Tower Research Capital (TRC)’s Spero Therapeutics SPRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-7,215
| Closed | -$16.8K | – | 5536 |
|
|
2025
Q4 | $16.8K | Buy |
+7,215
| New | +$16.8K | ﹤0.01% | 3235 |
|
|
2025
Q3 | – | Sell |
-603
| Closed | -$1.75K | – | 5601 |
|
|
2025
Q2 | $1.75K | Buy |
+603
| New | +$867 | ﹤0.01% | 4751 |
|
|
2025
Q1 | – | Sell |
-929
| Closed | -$957 | – | 5751 |
|
|
2024
Q4 | $957 | Buy |
929
+660
| +245% | +$785 | ﹤0.01% | 5125 |
|
|
2024
Q3 | $360 | Sell |
269
-7
| -3% | -$9 | ﹤0.01% | 5362 |
|
|
2024
Q2 | $359 | Buy |
276
+60
| +28% | +$91 | ﹤0.01% | 5348 |
|
|
2024
Q1 | $372 | Buy |
216
+215
| +21,500% | +$337 | ﹤0.01% | 5514 |
|
|
2023
Q4 | $1 | Sell |
1
-571
| -100% | -$681 | ﹤0.01% | 5895 |
|
|
2023
Q3 | $692 | Buy |
572
+537
| +1,534% | +$744 | ﹤0.01% | 5498 |
|
|
2023
Q2 | $51 | Sell |
35
-506
| -94% | -$866 | ﹤0.01% | 5869 |
|
|
2023
Q1 | $1K | Sell |
541
-32,623
| -98% | -$54.6K | ﹤0.01% | 5610 |
|
|
2022
Q4 | $57K | Buy |
33,164
+14,925
| +82% | +$27.9K | ﹤0.01% | 2259 |
|
|
2022
Q3 | $37K | Sell |
18,239
-6,838
| -27% | -$6.8K | ﹤0.01% | 3437 |
|
|
2022
Q2 | $19K | Buy |
25,077
+12,654
| +102% | +$36.8K | ﹤0.01% | 3858 |
|
|
2022
Q1 | $108K | Buy |
12,423
+3,655
| +42% | +$37.4K | ﹤0.01% | 2146 |
|
|
2021
Q4 | $141K | Buy |
8,768
+7,761
| +771% | +$123K | ﹤0.01% | 2013 |
|
|
2021
Q3 | $19K | Sell |
1,007
-7,377
| -88% | -$118K | ﹤0.01% | 3777 |
|
|
2021
Q2 | $117K | Buy |
8,384
+5,238
| +166% | +$73.2K | ﹤0.01% | 2304 |
|
|
2021
Q1 | $46K | Buy |
3,146
+1,986
| +171% | +$35K | ﹤0.01% | 3197 |
|
|
2020
Q4 | $22K | Sell |
1,160
-14,624
| -93% | -$228K | ﹤0.01% | 3815 |
|
|
2020
Q3 | $176K | Buy |
15,784
+13,043
| +476% | +$154K | ﹤0.01% | 2693 |
|
|
2020
Q2 | $37K | Buy |
+2,741
| New | +$30.8K | ﹤0.01% | 3284 |
|
|
2019
Q4 | – | Sell |
-223
| Closed | -$2K | – | 4302 |
|
|
2019
Q3 | $2K | Sell |
223
-495
| -69% | -$5.22K | ﹤0.01% | 3739 |
|
|
2019
Q2 | $8K | Buy |
+718
| New | +$8.64K | ﹤0.01% | 2712 |
|
|
2019
Q1 | – | Sell |
-1,120
| Closed | -$7K | – | 4246 |
|
|
2018
Q4 | $7K | Buy |
1,120
+1,082
| +2,847% | +$8.76K | ﹤0.01% | 2711 |
|
|
2018
Q3 | $0 | Sell |
38
-99
| -72% | -$1.15K | ﹤0.01% | 4212 |
|
|
2018
Q2 | $2K | Buy |
+137
| New | +$1.75K | ﹤0.01% | 3369 |
|
|
2018
Q1 | – | Sell |
-2,089
| Closed | -$24K | – | 3785 |
|
|
2017
Q4 | $24K | Buy |
+2,089
| New | +$25.6K | ﹤0.01% | 1927 |
|
Other funds holding SPRO
GP
P
VCM
AI
AFM
Tower Research Capital (TRC)'s SPRO Position: Q1 2026 in Review
Tower Research Capital (TRC) sold out of Spero Therapeutics (SPRO) in Q1 2026, closing a stake of 7,215 shares — an estimated $16.8K sold.
Tower Research Capital (TRC) first reported a position in SPRO in Q4 2017 and held it in 27 quarters. The position peaked at $176K in Q3 2020. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.
- Tower Research Capital (TRC) reported no remaining Spero Therapeutics position as of Q1 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 7,215 Spero Therapeutics shares in Q1 2026, an estimated $16.8K.
- Tower Research Capital (TRC) first reported a position in Spero Therapeutics in Q4 2017 and held it in 27 quarters.
- Tower Research Capital (TRC)'s Spero Therapeutics position peaked at $176K in Q3 2020.
- 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.